Shopping Cart
- Remove All
- Your shopping cart is currently empty
MRIA9, an ATP-competitive inhibitor targeting pan Salt-Inducible Kinases (SIK) and PAK2/3, demonstrates IC50 values of 516 nM, 180 nM, and 127 nM for SIK1, SIK2, and SIK3, respectively [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $598 | Backorder | |
10 mg | $954 | Backorder |
Description | MRIA9, an ATP-competitive inhibitor targeting pan Salt-Inducible Kinases (SIK) and PAK2/3, demonstrates IC50 values of 516 nM, 180 nM, and 127 nM for SIK1, SIK2, and SIK3, respectively [1]. |
In vitro | MRIA9 (5 μM) enhances sensitivity to paclitaxel in SKOV3 cells by inducing pronounced apoptosis[1]. In combination with paclitaxel (2 nM), MRIA9 significantly increases cell death in HeLa cells[1]. MRIA9 strongly impedes centrosome function, mispositions mitotic spindles in ovarian cancer cell lines, prevents centrosome disjunction during the late G2 phase, and sensitizes ovarian cancer cells and patient-derived 3D-spheroids to paclitaxel[2]. |
In vivo | MRIA9 exhibits high oral bioavailability (F = 75-80%)[1]. |
Molecular Weight | 496.92 |
Formula | C24H22ClFN6O3 |
Cas No. | 2750707-05-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.